Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Raises Target Price to $55
CVS Health Analyst Ratings
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $65
Evercore ISI Adjusts Price Target on CVS Health to $65 From $60, Maintains Outperform Rating
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $60
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $80
Piper Sandler Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $64
Bernstein Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $52
Bernstein Sticks to Their Hold Rating for CVS Health (CVS)
Argus Adjusts Price Target on CVS Health to $68 From $75
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $60
Evercore ISI Reaffirms Their Buy Rating on CVS Health (CVS)
TD Cowen Downgrades CVS Health(CVS.US) to Hold Rating, Maintains Target Price $80
TD Cowen Remains a Hold on CVS Health (CVS)
BofA Securities Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $63
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $60
CVS Health Is Maintained at Buy by Truist Securities
CVS Health Analyst Ratings
Rice downgraded CVS Health's target price to $58.
Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $58